ATE531366T1 - Zusammensetzungen und verfahren zur behandlung, verminderung, verbesserung oder linderung von erkrankungen des hinteren augensegments - Google Patents

Zusammensetzungen und verfahren zur behandlung, verminderung, verbesserung oder linderung von erkrankungen des hinteren augensegments

Info

Publication number
ATE531366T1
ATE531366T1 AT07813637T AT07813637T ATE531366T1 AT E531366 T1 ATE531366 T1 AT E531366T1 AT 07813637 T AT07813637 T AT 07813637T AT 07813637 T AT07813637 T AT 07813637T AT E531366 T1 ATE531366 T1 AT E531366T1
Authority
AT
Austria
Prior art keywords
compositions
treatment
relief
improvement
reduction
Prior art date
Application number
AT07813637T
Other languages
English (en)
Inventor
Raili Kerppola
Gary Phillips
Zhenze Hu
Keith Wayne Ward
Original Assignee
Bausch & Lomb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch & Lomb filed Critical Bausch & Lomb
Application granted granted Critical
Publication of ATE531366T1 publication Critical patent/ATE531366T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT07813637T 2006-08-07 2007-08-01 Zusammensetzungen und verfahren zur behandlung, verminderung, verbesserung oder linderung von erkrankungen des hinteren augensegments ATE531366T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83607806P 2006-08-07 2006-08-07
PCT/US2007/074943 WO2008021729A2 (en) 2006-08-07 2007-08-01 Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases

Publications (1)

Publication Number Publication Date
ATE531366T1 true ATE531366T1 (de) 2011-11-15

Family

ID=38823645

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07813637T ATE531366T1 (de) 2006-08-07 2007-08-01 Zusammensetzungen und verfahren zur behandlung, verminderung, verbesserung oder linderung von erkrankungen des hinteren augensegments

Country Status (19)

Country Link
US (1) US20080031884A1 (de)
EP (1) EP2051710B1 (de)
JP (1) JP2010500364A (de)
KR (1) KR20090051076A (de)
CN (1) CN101522187A (de)
AT (1) ATE531366T1 (de)
AU (1) AU2007284176B2 (de)
BR (1) BRPI0714817A2 (de)
CA (1) CA2660167C (de)
CY (1) CY1112269T1 (de)
DK (1) DK2051710T3 (de)
ES (1) ES2373999T3 (de)
HK (1) HK1127556A1 (de)
MX (1) MX2009001333A (de)
PL (1) PL2051710T3 (de)
PT (1) PT2051710E (de)
SI (1) SI2051710T1 (de)
TW (1) TWI378928B (de)
WO (1) WO2008021729A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2661607C (en) 2006-08-31 2012-06-26 Bausch & Lomb Incorporated Compositions and methods for treating or preventing glaucoma or progression thereof
US20090042936A1 (en) * 2007-08-10 2009-02-12 Ward Keith W Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation
JP2011502990A (ja) * 2007-11-05 2011-01-27 ボーシュ アンド ローム インコーポレイティド 薬物送達用ビヒクルとしての水非混和性物質
US20090239836A1 (en) * 2008-03-24 2009-09-24 Mary Lee Ciolkowski Multifunctional Ophthalmic Compositions
US20100008993A1 (en) * 2008-07-14 2010-01-14 Proksch Joel W Compositions and Methods for Increasing Bioavailability of Topical Ophthalmic Drugs
US20110077270A1 (en) * 2009-04-21 2011-03-31 Pfeffer Bruce A Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure
US20110189174A1 (en) * 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
RU2559585C2 (ru) * 2013-12-26 2015-08-10 Федеральное бюджетное учреждение науки "Уфимский научно-исследовательский институт медицины труда и экологии человека" Способ диагностики раннего воздействия вредных производственных факторов на организм работников, занятых в производстве синтетических смол не более 5 лет
KR20210119980A (ko) 2019-01-22 2021-10-06 아크리베스 바이오메디컬 게엠베하 손상된 피부 상처를 치료하기 위한 선택적 글루코코르티코이드 수용체 개질제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4580559A (en) * 1984-07-24 1986-04-08 Esperance Francis A L Indirect ophthalmoscopic photocoagulation delivery system for retinal surgery
AU4713499A (en) * 1998-06-27 2000-01-17 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
EP1521733B1 (de) * 2002-07-08 2014-08-20 Pfizer Products Inc. Modulatoren des glucocorticoid rezeptors
US7235662B2 (en) * 2003-06-11 2007-06-26 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
DE102004055633A1 (de) * 2004-11-12 2006-05-18 Schering Ag 5-substituierte Chinolin- und Isochinolin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer

Also Published As

Publication number Publication date
CA2660167C (en) 2012-04-10
BRPI0714817A2 (pt) 2013-05-21
MX2009001333A (es) 2009-02-13
AU2007284176A1 (en) 2008-02-21
TWI378928B (en) 2012-12-11
WO2008021729A2 (en) 2008-02-21
EP2051710A2 (de) 2009-04-29
HK1127556A1 (en) 2009-10-02
KR20090051076A (ko) 2009-05-20
WO2008021729A3 (en) 2008-10-09
CA2660167A1 (en) 2008-02-21
EP2051710B1 (de) 2011-11-02
PT2051710E (pt) 2012-02-08
PL2051710T3 (pl) 2012-03-30
DK2051710T3 (da) 2012-02-20
JP2010500364A (ja) 2010-01-07
CY1112269T1 (el) 2015-12-09
US20080031884A1 (en) 2008-02-07
ES2373999T3 (es) 2012-02-10
AU2007284176B2 (en) 2013-03-28
SI2051710T1 (sl) 2012-02-29
TW200815416A (en) 2008-04-01
CN101522187A (zh) 2009-09-02

Similar Documents

Publication Publication Date Title
ATE531366T1 (de) Zusammensetzungen und verfahren zur behandlung, verminderung, verbesserung oder linderung von erkrankungen des hinteren augensegments
AR049955A1 (es) Composiciones y metodos para el tratamiento de trastornos metabolicos
BRPI0414277A (pt) métodos e composições para o tratamento de dor e outras condições mediadas adrenérgicas alfa 2
MX2009009624A (es) Droxidopa y composicion farmaceutica de la misma para el tratamiento de la fibromialgia.
WO2003068171A3 (en) Method and composition for treatment of inflammation and aids-associated neurological disorders
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
ECSP088762A (es) Tratamiento del dolor
EP2331095A4 (de) Bestimmte kynurenin-3-monooxygenase-inhibitoren, pharmazeutische zusammensetzungen und anwendungsverfahren dafür
WO2008089307A3 (en) Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
MY151018A (en) Use of nutritional compositions for preventing disorders
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
WO2007085018A3 (en) Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution
MX2013011314A (es) Tratamientos oftalmicos.
BRPI0408902A (pt) composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca
MX2021000376A (es) Composiciones tópicas para el alivio del dolor.
UA90668C2 (ru) Состав для лечения хронической венозной недостаточности, который содержит водный экстракт листьев красного винограда и противовоспалительное средство
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
BR112014030279A2 (pt) métodos para tratamento de neutropenia usando agonistas retinóide
WO2008112773A3 (en) Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
ZA202110111B (en) Methods and compositions for treating liver disorders
TW200511996A (en) The use of steroids to treat persons suffering from ocular disorders
ATE506061T1 (de) Zusammensetzungen und verfahren zur behandlung, kontrolle, verminderung, verbesserung bzw. prävention von allergien
BR0308584A (pt) Composição farmacêutica androgênica e método para tratamento de depressão
DE60229240D1 (de) Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2051710

Country of ref document: EP